Welcome to the Stocktwits Top 25 Newsletter this week!

The Stocktwits Top 25 reports the 25 best-performing stocks in the S&P 500, Nasdaq 100, and Russell 2000 year to date and tracks their performances over time. To help you understand this data further, check out our FAQ page, and feel free to reach out if you have questions!

Here are the Stocktwits Top 25 Lists for this week:

Milestone Pharmaceuticals (NASDAQ: MIST) is building long-term value through a targeted cardiovascular strategy. We are a commercial-stage company who developed and launched the first FDA-approved product to treat paroxysmal supraventricular tachycardia (PSVT) in more than 30 years. Our pipeline includes Phase 3 research of atrial fibrillation with rapid ventricular rate.

*3rd Party Ad. Not an offer or recommendation by Stocktwits. See disclosure here.

This sponsored article is for informational purposes only and does not constitute investment advice.

This week's Russell 2000 board is all AI infrastructure spillover, with one reverse split masquerading as a comeback and one biotech binary still on the clock.

$PENG ( ▼ 3.74% ) : Penguin Solutions, $4B cap: This week's top dawg, jumping 12 spots from #24 to #12. The move followed a blowout fiscal Q3 print on July 7 (revenue up 48% year over year, EPS nearly doubling estimates) and Nvidia naming it an AI Factory Specialized Partner. WTD up 27.5%, sentiment at 71%. Risk: the multiple. Shares trade near 60x earnings, and the stock has already logged 38 moves over 5% in a year.

$BAND ( ▼ 3.77% ) : Bandwidth, $2.4B cap: Climbed 4 spots to #6 after B. Riley hiked its price target 55% to $85 on AI voice infrastructure demand. WTD up 22.5%, sentiment at 66%. Risk: shares are sitting just under the $72.64 conversion price on its new 2032 convertible notes, a level that tends to cap upside.

$SVC ( ▲ 0.91% ) : Service Properties Trust, $1.1B cap: New entrant at #7, but the "move" is a 1-for-5 reverse split effective July 6, not fresh buying. Risk: the reverse split doesn't fix the balance sheet. The REIT has cut its distribution before and still carries heavy leverage against a hotel portfolio facing margin pressure.

$ATOM ( ▼ 2.93% ) : Atomera, $260M cap: Fell 10 spots to #25, the worst drop on the list. WTD down 10.5%, breaking below its short-term trend floor. Risk: cash burn is real (negative operating margin in the thousands of percent) and a law firm is actively investigating potential securities claims against its executives.

$SLS ( ▼ 5.55% ) : SELLAS Life Sciences, $2.5B cap: Fell 7 spots to #18 after a WallStreetBets-driven near-double unwound just as fast. WTD down 14.8%, watchers at 58.5k. Risk: binary catalyst. The Phase 3 REGAL AML trial has hit 78 of 80 required survival events; the topline readout could send this either way hard. Position-size accordingly.

Next week's swing factor: SELLAS hitting the 80th REGAL event. A clean survival benefit reprices the whole biotech corner of this list; a miss drags SLS and reignites bear chatter on the other AI-adjacent names riding pure multiple expansion.

Help us deliver the best content possible by completing this brief survey. 📝

Want to see some change? Email Kevin Travers your feedback; follow him on Stocktwits.

Securities Disclaimer: STOCKTWITS IS NOT A TAX ADVISOR, BROKER, FINANCIAL ADVISOR OR INVESTMENT ADVISOR. THE SERVICE IS NOT INTENDED TO PROVIDE TAX, LEGAL, FINANCIAL OR INVESTMENT ADVICE, AND NOTHING ON THE SERVICE SHOULD BE CONSTRUED AS AN OFFER TO SELL, A SOLICITATION OF AN OFFER TO BUY, OR A RECOMMENDATION FOR ANY SECURITY. Trading in such securities can result in immediate and substantial losses of the capital invested. You should only invest risk capital, and not capital required for other purposes. You alone are solely responsible for determining whether any investment, security or strategy, or any other product or service, is appropriate or suitable for you based on your investment objectives and personal and financial situation. You should also consult an attorney or tax professional regarding your specific legal or tax situation. The Content is to be used for informational and entertainment purposes only and the Service does not provide investment advice for any individual. Stocktwits, its affiliates and partners specifically disclaim any and all liability or loss arising out of any action taken in reliance on Content, including but not limited to market value or other loss on the sale or purchase of any company, property, product, service, security, instrument, or any other matter. You understand that an investment in any security is subject to a number of risks, and that discussions of any security published on the Service will not contain a list or description of relevant risk factors. In addition, please note that some of the stocks about which Content is published on the Service have a low market capitalization and/or insufficient public float. Such stocks are subject to more risk than stocks of larger companies, including greater volatility, lower liquidity and less publicly available information. Read the full terms & conditions here. 🔍

Author Disclosure: The author of this newsletter does not hold positions in any of the securities or assets mentioned. 📋